American Capital Advisory’s Quest Diagnostics DGX Stock Holding History

American Capital Advisory’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$424	Sell	2 -1	-33%	-$196	﹤0.01%	986
2026 Q1	$588	Hold	3	–	–	﹤0.01%	813
2025 Q4	$521	Hold	3	–	–	﹤0.01%	742
2025 Q3	$572	Buy	3 +2	+200%	+$355	﹤0.01%	661
2025 Q2	$180	Sell	1 -1	-50%	-$174	﹤0.01%	810
2025 Q1	$339	Buy	+2	New	+$329	﹤0.01%	583
2024 Q2	–	Sell	-4	Closed	-$566	–	460
2024 Q1	$566	Buy	+4	New	+$519	﹤0.01%	409

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

American Capital Advisory's DGX Position: Q2 2026 in Review

American Capital Advisory reduced its Quest Diagnostics (DGX) stake by 33% in Q2 2026, selling an estimated $196 and leaving 2 shares worth $424. The position accounts for ﹤0.01% of the portfolio, ranked #986.

American Capital Advisory first reported a position in DGX in Q1 2024 and has held it in 7 quarters since. The position peaked at $588 in Q1 2026. 629 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

American Capital Advisory held 2 shares of Quest Diagnostics worth $424 as of Q2 2026.
American Capital Advisory sold 1 Quest Diagnostics share in Q2 2026, an estimated $196.
Quest Diagnostics made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #986 holding.
American Capital Advisory first reported a position in Quest Diagnostics in Q1 2024 and has held it in 7 quarters since.
American Capital Advisory's Quest Diagnostics position peaked at $588 in Q1 2026.
629 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.